8th Health Technology Assessment

Η Μάγδα Χατζίκου, Partner PharmEcons Easy Access Ltd, ΣΕΠ Ελληνικό Ανοικτό Πανεπιστήμιο στο πλαίσιο της ομιλίας της στο 8ο Ετήσιο Συνέδριο ΗΤΑ με παράδειγμα την εφαρμογή HosmartAI (ένα επιδοτούμενο πρόγραμμα του Ορίζοντα 2020), αναφέρθηκε στην ανάγκη να τεθεί σύντομα το πλαίσιο αξιολόγησης των ιατροτεχνολογικών εφαρμογών και άλλων τεχνολογιών τεχνητής νοημοσύνης και στην Ελλάδα.

Continue reading

Proposal on the European Health Data Space

The European Health Data Space (‘EHDS’) is the first proposal of such domain-specific common European data spaces. It will address health-specific challenges to electronic health data access and sharing, is one of the priorities of the European Commission in the area of health 2 and will be an integral part of building a European Health Union.

Continue reading

Patient preferences for breast cancer treatments: a discrete choice experiment in France, Ireland, Poland, Spain

The authors wanted to explore what breast cancer patients want the most from their cancer
treatments. For this purpose, their preferences were collected in four European countries via a discrete
choice experiment. The study showed that patients prefer treatments that improve their ability to function
well in their daily lives and reduce their levels of pain. Patients’ preferences for treatment outcomes might
differ from those of the treating clinicians or regulators. Hence, these aspects can be discussed with their
clinicians to make a joint decision on the choice of treatments.

Continue reading

Regulation on health technology assessment

The Regulation (EU) 2021/2282 on health technology assessment (HTAR) contributes to improving the availability for EU patients of innovative technologies in the area of health, such as medicines and certain medical devices. It ensures an efficient use of resources and strengthens the quality of HTA across the Union.
It provides a transparent and inclusive framework by establishing a Coordination Group of HTA national or regional authorities, a stakeholder network and by laying down rules on the involvement in joint clinical assessments and joint scientific con-sultations of patients, clinical experts and other relevant experts.
The HTAR will also reduce duplication of efforts for national HTA authorities and industry, facilitate business predictability and ensure the long-term sustainability of EU HTA cooperation.

Continue reading

MCR Disease Management of Metastatic Melanoma

Disease Management and Resource Use for the Management of Melanoma stage IIIc or IV Positive for BRAF V600 Mutations in Greece

Objective: Melanoma is one of the most aggressive cancers and is responsible for the majority of skin cancer deaths, with the
presence of metastases prognostic for poor survival. At a time when most cancer incidences are falling, the annual incidence
of melanoma has risen as rapidly as 4-6% in many European countries, with a substantial economic burden in advanced
stages. The objective of this study is the investigation of treatment pathways and healthcare resource use related to advanced
BRAF-mutated melanoma in Greece.

Continue reading


HosmartAI EU Project, an amazing and ambitious journey for Pharmecons Easy Access who will perform the economic evaluation of the AI technologies has just started!

On the last 9-10 February, took place the kick-off meeting of the new project HosmartAI –
“Hospital Smart development based on AI”. The project is funded by €10 million under European
Union’s Horizon 2020 research and innovation programme (Grant Agreement No 101016834).

Continue reading

Hellenic Atherosclerosis Society

Η Ελληνική Εταιρία Αθηροσκλήρωσης σε συνεργασία με τη συμβουλευτική εταιρία Pharmecons Easy Access που εξειδικεύεται σε θέματα τιμολόγησης και αποζημίωσης τεχνολογιών υγείας στην Ευρώπη και στην Ελλάδα διοργανώνει πρόγραμμα/σεμινάριο (satellite) στο πλαίσιο του ετήσιου συνεδρίου της Ελληνικής Εταιρίας Αθηροσκλήρωσης, την Πέμπτη 29 Νοεμβρίου 2018 και ώρα 11:00-15:00 στο Ξενοδοχείο Divani Caravel, αίθουσα Μυκήνες.

Health Technology Assessment HTA | Εκπαιδευτικό Σεμινάριο – Ελληνική Εταιρεία Αθηροσκλήρωσης (atherosclerosis.gr)

HTA Seminar PEF 2018

Σεμινάριο Οικονομικών Φαρμάκων

Αξιολόγηση και Αποζημίωση φαρμάκων: Νέα δεδομένα

Continue reading